p53, bcl-2, and Bax Expression in Renal Cell Carcinoma - immunohistochemical detection of p53 protein versus clinicopathologic parameters

By Vasavada S.P.   Novick A.C.   Williams B.R.G.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 1057-1061

Elsevier

Access to resources Recommend Favorite

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53

By Stricker H.J.   Jay J.K.   Linden M.D.   Tamboli P.   Amin M.B.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 366-369

Elsevier

Access to resources Recommend Favorite

Limitations of tissue microarrays in the evaluation of bcl-2 and P53 expression in whole mount derived prostate tissues

By Merseburger A.   Kuczyk M.   Moul J.   Sesterchenn I.   Jonas U.   Srivastava S.   Mostofi E.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 59-59

Elsevier

Access to resources Recommend Favorite

Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone?

By Lee W.R.   Hanlon A.   Hanks G.E.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 704-707

Elsevier

Access to resources Recommend Favorite

Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer

By Linjawi A.   Kontogiannea M.   Halwani F.   Edwardes M.   Meterissian S.  

Journal of the American College of Surgeons, Vol. 198, Iss. 1, 2004-01 ,pp. : 83-90

Elsevier

Access to resources Recommend Favorite